BR0316163A - Inibidores de histona desacetilase para tratamento de doenças degenerativas do olho - Google Patents

Inibidores de histona desacetilase para tratamento de doenças degenerativas do olho

Info

Publication number
BR0316163A
BR0316163A BR0316163-3A BR0316163A BR0316163A BR 0316163 A BR0316163 A BR 0316163A BR 0316163 A BR0316163 A BR 0316163A BR 0316163 A BR0316163 A BR 0316163A
Authority
BR
Brazil
Prior art keywords
treatment
histone deacetylase
deacetylase inhibitors
eye diseases
degenerative eye
Prior art date
Application number
BR0316163-3A
Other languages
English (en)
Inventor
Peggy E Hellberg
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of BR0316163A publication Critical patent/BR0316163A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"INIBIDORES DE HISTONA DESACETILASE PARA TRATAMENTO DE DOENçAS DEGENERATIVAS DO OLHO". A presente invenção refere-se a composições e processos para tratar condições degenerativas e doenças do olho com inibidores de histona desacetilase.
BR0316163-3A 2002-11-12 2003-10-27 Inibidores de histona desacetilase para tratamento de doenças degenerativas do olho BR0316163A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42557602P 2002-11-12 2002-11-12
PCT/US2003/033873 WO2004043348A2 (en) 2002-11-12 2003-10-27 Histone deacetylase inhibitors for treating degenerative diseases of the eye

Publications (1)

Publication Number Publication Date
BR0316163A true BR0316163A (pt) 2005-09-27

Family

ID=32313019

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316163-3A BR0316163A (pt) 2002-11-12 2003-10-27 Inibidores de histona desacetilase para tratamento de doenças degenerativas do olho

Country Status (12)

Country Link
US (2) US20040092431A1 (pt)
EP (1) EP1562592A4 (pt)
JP (1) JP2006508120A (pt)
KR (1) KR20050074547A (pt)
CN (1) CN1711086A (pt)
AU (1) AU2003286686B2 (pt)
BR (1) BR0316163A (pt)
CA (1) CA2504226A1 (pt)
MX (1) MXPA05004738A (pt)
RU (1) RU2324483C2 (pt)
WO (1) WO2004043348A2 (pt)
ZA (1) ZA200503230B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2324483C2 (ru) * 2002-11-12 2008-05-20 Алькон, Инк. Ингибиторы гистондеацетилазы для лечения дегенеративных заболеваний глаз
US20080004311A1 (en) * 2002-11-12 2008-01-03 Alcon, Inc. Histone deacetylase inhibitors for treating degenerative diseases of the eye
WO2004043352A2 (en) * 2002-11-12 2004-05-27 Alcon, Inc. Histone deacetylase inhibitors for the treatment of ocular neovascular or edematous disorders and diseases
US20050197336A1 (en) * 2004-03-08 2005-09-08 Miikana Therapeutics Corporation Inhibitors of histone deacetylase
US7345043B2 (en) * 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
GB2417682A (en) * 2004-08-18 2006-03-08 Univ East Anglia Histone deacetylse inhibitor for treating connective tissue disorders
JP2008530136A (ja) 2005-02-14 2008-08-07 ミイカナ セラピューティクス インコーポレイテッド ヒストンデアセチラーゼの阻害剤として有用な縮合複素環化合物
AU2006270322A1 (en) 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2616537A1 (en) * 2005-07-27 2007-02-01 University Of Florida Research Foundation, Inc. Small compounds that correct protein misfolding and uses thereof
CN101646651A (zh) 2007-03-28 2010-02-10 参天制药株式会社 具有脲结构的新型吡啶羧酸（2-氨基苯基）酰胺衍生物
WO2008117861A1 (ja) * 2007-03-28 2008-10-02 Santen Pharmaceutical Co., Ltd. フェニレンジアミン誘導体を有効成分とする眼圧下降剤
CA2680838A1 (en) * 2007-03-28 2008-10-16 Santen Pharmaceutical Co., Ltd. Intraocular pressure-lowering agent comprising compound having histone deacetylase inhibitory effect as active ingredient
ES2389754T3 (es) 2008-05-23 2012-10-31 Santen Pharmaceutical Co., Ltd Nuevos derivados de tiofendiamina con estructura urea
BR112012030193B1 (pt) * 2010-05-27 2020-11-17 The Regents Of The University Of Colorado, A Body Corporate Com postos m acrocíclico s inibidores de histona desacetilases, com posições farmacêuticas e seus usos
CN107362148B (zh) * 2017-07-27 2020-04-21 东曜药业有限公司 一种治疗肿瘤的药物组合物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534580A1 (fr) * 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
US5151444B1 (en) * 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
US5321128A (en) * 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
EP0569046B1 (en) * 1988-09-06 2002-11-13 Pharmacia Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5464866A (en) * 1992-08-17 1995-11-07 Alcon Laboratories, Inc. Substituted hydrindanes for the treatment of angiogenesis-dependent diseases
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5688819A (en) * 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5681854A (en) * 1995-11-22 1997-10-28 Alcon Laboratories, Inc. Use of aliphatic carboxylic acid derivatives in ophthalmic disorders
AUPP505798A0 (en) * 1998-08-04 1998-08-27 Fujisawa Pharmaceutical Co., Ltd. Novel compound fr225497 substance
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US7154002B1 (en) * 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) * 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
RU2324483C2 (ru) * 2002-11-12 2008-05-20 Алькон, Инк. Ингибиторы гистондеацетилазы для лечения дегенеративных заболеваний глаз
US20080004311A1 (en) * 2002-11-12 2008-01-03 Alcon, Inc. Histone deacetylase inhibitors for treating degenerative diseases of the eye
US8034768B2 (en) * 2007-06-22 2011-10-11 Board Of Regents, The University Of Texas System Composition and method for the treatment of diseases affected by histone deacetylase inhibitors

Also Published As

Publication number Publication date
JP2006508120A (ja) 2006-03-09
WO2004043348A2 (en) 2004-05-27
CA2504226A1 (en) 2004-05-27
WO2004043348A3 (en) 2004-07-15
ZA200503230B (en) 2006-06-28
RU2005118108A (ru) 2006-01-20
EP1562592A4 (en) 2009-01-21
CN1711086A (zh) 2005-12-21
EP1562592A2 (en) 2005-08-17
AU2003286686A1 (en) 2004-06-03
US20070088045A1 (en) 2007-04-19
KR20050074547A (ko) 2005-07-18
MXPA05004738A (es) 2005-08-03
RU2324483C2 (ru) 2008-05-20
AU2003286686B2 (en) 2009-07-16
US20040092431A1 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
BR0316163A (pt) Inibidores de histona desacetilase para tratamento de doenças degenerativas do olho
BR0316606A (pt) Derivados de aminoindazóis e sua utilização como inibidores de quinases
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
DE60332367D1 (de) Hemmer des abbaus der extrazellulären matrix von arthrodia-knorpel
BR0316206A (pt) Uso inibidores de histona desacetilase para o tratamento de distúrbios e de doenças oculares neovasculares ou edematosos
BR0313282A (pt) Composições de inibidor seletivo de ciclooxigenase-2 e um inibidor de anidrase carbÈnica para o tratamento de neoplasia
GB0223040D0 (en) Therapeutic compounds
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
NO20061253L (no) Acetylenderivater som inhibitorer av histon deacetylase
BR0310092A (pt) Combinação de compostos orgânicos
BRPI0514395A (pt) uso terapêutico de inibidores de rtp801
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
BRPI0519424A2 (pt) composiÇÕes e mÉtodos para tratamento de distérbios de proliferaÇço celular
ATE416761T1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
ATE463490T1 (de) Histondeacetylase-hemmer
BRPI0415167A (pt) composto de amina como ligandos de canal de ìon e usos dos mesmos
BRPI0409624A (pt) 2-hidróxi-3-diaminoalcanos de benzamida
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BRPI0415179A (pt) derivados de amida como ligandos de canal de ìon e composições farmacêuticas e métodos de empregar as mesmas
BR0015698A (pt) Composições e métodos para tratamento de doenças alérgicas
ATE554169T1 (de) Smad7-inhibitoren zur behandlung von krankheiten des zns
BR0214672A (pt) Inibidores de fosfolipase citosólica a2
BRPI0411864A (pt) combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas
CY1109975T1 (el) Παρα-αλκυλ-υποκατεστημενα αμιδια ν-(4-υδροξυ-3-μεθοξυ-βενζυλο) κιναμμωμικου οξεος και η χρησιμοποιηση τους για την παρασκευη φαρμακων

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI. A61K 31/435, A61P 27/02, A61P 27/00

Ipc: A61K 31/435 (2011.01), A61P 27/02 (2011.01), A61P

B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A E 10A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2257 DE 08/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A, 16A E 17A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.